Literature DB >> 11796231

Retinoids and their receptors in cancer development and chemoprevention.

Shi-Yong Sun1, Reuben Lotan.   

Abstract

Retinoids play an important role in regulating the growth and differentiation of normal, premalignant and malignant cell types, especially epithelial cells, mainly through interaction with two types of nuclear receptors: retinoic acid receptors (RARalpha, beta and gamma) and retinoid X receptors (RXRalpha, beta and gamma). Vitamin A deficiency in experimental animals has been associated with a higher incidence of cancer and with increased susceptibility to chemical carcinogens. This is in agreement with the epidemiological studies indicating that individuals with a lower dietary vitamin A intake are at a higher risk to develop cancer. At the molecular level, aberrant expression and function of nuclear retinoid receptors have been found in various types of cancer including premalignant lesions. Thus, aberrations in retinoid signaling are early events in carcinogenesis. Retinoids at pharmacological doses exhibit a variety of effects associated with cancer prevention. They suppress transformation of cells in vitro, inhibit carcinogenesis in various organs in animal models, reduce premalignant human epithelial lesions and prevent second primary tumors following curative therapy for epithelial malignancies such as head and neck, lung, liver, and breast cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11796231     DOI: 10.1016/s1040-8428(01)00144-5

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  72 in total

1.  Nanostructured lipid carriers (NLC) for parenteral delivery of an anticancer drug.

Authors:  Akhayacatra Chinsriwongkul; Ponwanit Chareanputtakhun; Tanasait Ngawhirunpat; Theerasak Rojanarata; Warisada Sila-on; Uracha Ruktanonchai; Praneet Opanasopit
Journal:  AAPS PharmSciTech       Date:  2011-12-14       Impact factor: 3.246

Review 2.  Retinoid pathway and cancer therapeutics.

Authors:  Nathan Bushue; Yu-Jui Yvonne Wan
Journal:  Adv Drug Deliv Rev       Date:  2010-08-03       Impact factor: 15.470

3.  Chemoprevention of esophageal adenocarcinoma.

Authors:  Julian A Abrams
Journal:  Therap Adv Gastroenterol       Date:  2008-07       Impact factor: 4.409

4.  Uptake of all-trans retinoic acid-containing aerosol by inhalation to lungs in a guinea pig model system--a pilot study.

Authors:  Michael W Schäffer; Somdutta Sinha Roy; Shyamali Mukherjee; David E Ong; Salil K Das
Journal:  Exp Lung Res       Date:  2010-12       Impact factor: 2.459

Review 5.  Updated Physician's Guide to the Off-label Uses of Oral Isotretinoin.

Authors:  Steven Brandon Nickle; Nathan Peterson; Michael Peterson
Journal:  J Clin Aesthet Dermatol       Date:  2014-04

Review 6.  Headway and hurdles in the clinical development of dietary phytochemicals for cancer therapy and prevention: lessons learned from vitamin A derivatives.

Authors:  Christina Y Yim; Pingping Mao; Michael J Spinella
Journal:  AAPS J       Date:  2014-01-16       Impact factor: 4.009

7.  Altered localization of retinoid X receptor alpha coincides with loss of retinoid responsiveness in human breast cancer MDA-MB-231 cells.

Authors:  T Tanaka; B L Dancheck; L C Trifiletti; R E Birnkrant; B J Taylor; S H Garfield; U Thorgeirsson; L M De Luca
Journal:  Mol Cell Biol       Date:  2004-05       Impact factor: 4.272

8.  Oral carcinogenesis induced by 4-nitroquinoline 1-oxide in lecithin:retinol acyltransferase gene knockout mice.

Authors:  Limin Liu; Xiao-Han Tang; Theresa Scognamiglio; Lorraine J Gudas
Journal:  J Nutr Biochem       Date:  2009-12-01       Impact factor: 6.048

Review 9.  The role of CYP26 enzymes in retinoic acid clearance.

Authors:  Jayne E Thatcher; Nina Isoherranen
Journal:  Expert Opin Drug Metab Toxicol       Date:  2009-08       Impact factor: 4.481

10.  Tumor suppressor IRF-1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL.

Authors:  Nicole Clarke; Ana M Jimenez-Lara; Emilie Voltz; Hinrich Gronemeyer
Journal:  EMBO J       Date:  2004-07-08       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.